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A general [18F]AlF radiochemistry procedure on
two automated synthesis platforms†
L. Allott,‡ C. Da Pieve,‡ D. R. Turton and G. Smith*
The aluminium fluoride-18 ([18F]AlF) radiolabelling procedure has generated great interest because it is a
simple, one-pot method that can be used to directly radiolabel small molecules, peptides and proteins
without the requirement for a [18F]fluoride drying step. Reported here is the development of an automated
[18F]AlF radiolabelling procedure of three different precursors (one small molecule and two peptides) on
two automated synthesis platforms: GE TRACERlab FXFN and Trasis AllInOne (AIO). Aiming at the clinical
translatability of a [18F]AlF radiosynthetic methodology, the use of both platforms yielded radioconjugates
with >98% radiochemical purity (RCP) within 26–35 min and required a single rapid purification step. The
Trasis AIO platform gave improved [18F]fluoride incorporation, and generally produced radioconjugates with
a higher radiochemical yield (RCY) and effective specific activities (SA) when compared to the GE
TRACERlab FXFN system.
Introduction
Positron emission tomography (PET) is an imaging modality
used to diagnose and stage diseases by quantitatively monitor-
ing the in vivo distribution of a positron emitting radionuclide
bound by chelation or covalent bonding to a biological
targeting molecule. Fluorine-18 is often considered the “ideal”
PET radioisotope due to a combination of its high positron
emission (97%), low positron energy (β+max = 0.64 MeV) ensur-
ing relatively high resolution images and its half-life (109.8
min) which is compatible with multistep synthesis and off-site
transport.1 Generally, the incorporation of fluorine-18 into
small organic molecules requires high temperatures and the
use of organic solvents; unfortunately these conditions are un-
suitable for the labelling of biomolecules such as peptides and
small proteins.2 As a consequence, their radiolabelling can be
achieved by a post-radiolabelling attachment of fluorine-18
containing small molecules e.g. N-succinimidyl 4-[18F]-
fluorobenzoate ([18F]SFB) using mild aqueous conditions.3
Recently, investigation into the direct radiolabelling of bio-
molecules with fluorine-18 yielded a one-step procedure
comprising the chelation of the aluminium fluoride-18 com-
plex ([18F]AlF) by a macrocyclic ligand (i.e. NOTA, NODA).4–7
The rapid [18F]AlF technique has generated significant interest
owing to the combination of convenient metal based radio-
chemistry and the excellent decay characteristics of fluorine-
18. This approach has been used to successfully radiolabel
clickable tags, peptides and small proteins.5,8–12
McBride et al. described the preparation of a lyophilised
kit which provided a potential starting point for the
standardised production of [18F]AlF-based radiopharmaceuti-
cals.7 Additionally, Yu et al. reported the feasibility of [18F]AlF
radiolabelled NOTA-PRGD2 “[18F]Alfatide” in healthy volun-
teers and in patients with brain metastases.13 This demon-
strates an increased interest in applying the [18F]AlF
radiolabelling technique for the preparation of radiopharma-
ceuticals for clinical application.
This study describes the development of a general [18F]AlF
automated radiolabelling procedure. Two different platforms,
a GE TRACERlab FXFN and a Trasis AllInOne (AIO), were
trialled and three azamacrocycle-containing substrates were
radiolabelled (Fig. 1). NOTA-octreotide and NOTA-RGDfK were
selected because they are commercially available and have
been previously extensively radiolabelled using the [18F]AlF
method.14–16 The tetrazine functionalised NODA macrocycle
(NODA-Tz) was used as a representative of small molecules.
Compounds having a similar structure to NODA-Tz have been
radiolabelled with the [18F]AlF complex and employed for the
bioorthogonal pre-clinical imaging of tumour xenografts in
mice.8 The two automated platforms used in the study are
widely used for the production of radiopharmaceuticals under
GMP conditions.
The GE TRACERlab FXFN is built around a fixed reactor
vessel with components which are attached to fixed locations.
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Reagents are manipulated from glass reservoirs to the reactor
by gas pressure. The Trasis AIO platform is a cassette based
system that mimics hands on processes (e.g. with the use of
replaceable syringes and plastic manifolds) by using syringe
drives and tap turners; as the cassette is a disposable compo-
nent, the synthesis is more GMP compatible than a fixed re-
actor system. Additionally, the platforms are managed by two
different types of automation software. In the GE TRACERlab
FXFN system, the process is controlled by a time list with only
limited feedback from the platform. The Trasis AIO process
is controlled by a combination of timed steps and feedback
from the platform regarding that the correct syringe position,
temperature or pressure has been achieved.
In this study, the radiolabelling was initially investigated
on the GE TRACERlab FXFN system to find indicative trends
in radiolabelling performance by changing reaction condi-
tions (e.g. volumes, buffer and substrate quantities) which
were subsequently applied to the Trasis AIO platform.
Results and discussion
Selection and preparation of the substrates
Two commercially available azamacrocycle-conjugated pep-
tides (NOTA-octreotide and NOTA-RGDfK) and the non-
commercially available tetrazine functionalised 1,4,7-
triazacyclononane-1,4-diacetic acid (NODA-Tz) were selected
for this study to represent the different molecules which have
been radiolabelled via the [18F]AlF method (Fig. 1).
The NODA-Tz small molecule (4) has been designed and
synthesised in our lab (Scheme 1). Having previously shown
a high [18F]AlF radiolabelling efficiency, the NODA macro-
cycle was chosen in preference to the more commonly used
NOTA chelator.5,17 In brief, product 4 was prepared by
attaching a 6-carbon alkyl linker to 4-cyanophenol to access
compound 1 which was converted into tetrazine 2 in one step
following a simple literature procedure.18 Tetrazine 3, derived
from the tosylation of 2, was reacted with NO2AtBu and sub-
sequently deprotected using TFA. The desired product 4 was
obtained in a high purity after RP-HPLC purification. All puri-
fied compounds were characterised by 1H and 13C-NMR and
ESI-HRMS (ESI†).
[18F]AlF radiolabelling conditions using GE TRACERlab FXFN
automated synthesis platform
Previously, [18F]AlF radiolabelling has been performed by
hand using non-purified [18F]fluoride (i.e. not treated to re-
move metal residues) with an optimal reaction pH of 4 which
Fig. 1 The three different azamacrocycle-containing substrates used in the study: NODA-Tz (A), NOTA-octreotide (B), NOTA-RGDfK (C) and the
general radiolabelling reaction (insert).
Scheme 1 Synthesis of NODA-Tz (4). Reaction conditions: a) 6-bromohexanol, K2CO3, acetone, 56 °C, 24 h; b) hydrazine hydrate, NiĲOTf)2, MeCN,
60 °C, 16 h; c) p-toluenesulfonyl chloride, TEA, DCM, r.t., 16 h; d) i. NO2AtBu, DIPEA, DMF, RT, 16 h; ii. TFA, RT, 2 h.
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is usually achieved using small volumes of a concentrated
buffer solution (e.g. 10 μl of 0.5 M NaOAc).5 The reaction
mixture is then incubated at 100–105 °C for 15 min and a
small excess of the macrocycle-conjugate over Al3+ is
recommended.14 Typically, the presence of an organic co-
solvent (ethanol or acetonitrile) improved the radiolabelling
efficiency.15 Generally, the lowest achievable final reaction
volumes (i.e. highest conjugate concentration) and acetate
ion concentration afforded increased radiolabelling yields.14
Both automation systems used in this study are designed for
handling large volumes of liquid and therefore the conven-
tional [18F]AlF radiolabelling conditions required modifica-
tion. To improve the RCY, a glass reactor was used for the
radiolabelling of peptides, while a glassy carbon reactor was
used for the NODA-Tz. For an efficient transfer to the reac-
tion vessel, the substrate was dissolved in NaOAc buffer (ca.
100 μL, 25 mM, pH 4) and a portion of the organic co-solvent
(100 μL). The volume of NaOAc was carefully selected to
buffer the [18F]fluoride (300–380 μl aliquot, ca. 1000 MBq, of
ca. 2 mL target water) to the optimal pH of 4 while
minimising the effect of dilution on the radiolabelling effi-
ciency. A conjugate to AlCl3 molar ratio of 1 : 0.9 was used.
Acetonitrile was selected as the organic co-solvent for the
NODA-Tz substrate due to poor solubility in ethanol. The
radiolabelling of NOTA-RGDfK and NOTA-octreotide sub-
strates using a different co-solvent (i.e. ethanol) resulted in
no difference in performance (RCYs). Acetonitrile was used
with all three substrates to ensure consistency of the general
method. The co-solvent was used in an aqueous solution in
the ratio of 1 : 1.2 (v/v) which was found to give the best [18F]
AlF incorporation without loss of efficiency due to excessive
dilution (data not shown). An efficient radiolabelling, without
degrading the structural integrity of the molecules, was
achieved by incubating the mixture at 105 °C for 15 min. The
use of ascorbic acid as a radioprotector was necessary for
peptide labelling as extensive radiolysis was observed (Fig.
S1, S3B and S4B†). A radioprotector was not required for the
radiosynthesis of [18F]AlF-NODA-Tz.
If larger volumes of [18F]fluoride are to be used, a concen-
tration step using an anion exchange cartridge could be
employed and placed before the reactor on the GE
TRACERlab FXFN (Fig. 2) and eluted following the procedure
described by Meyer et al.8 Alternatively, the production of a
high radioactive concentration of [18F]fluoride for clinical
Fig. 2 Schematic representation of the [18F]AlF radiochemistry set up (A) and overview of the automated radiolabelling processes (B) for the GE
TRACERlab FXFN system. If necessary, an anion exchange cartridge can be placed between V10 and V11 to concentrate the [
18F]fluoride solution
followed by elution into the reaction vessel from V1.
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applications will remove the necessity of a [18F]fluoride con-
centration procedure; instead, a concentrated [18F]fluoride al-
iquot (300–380 μL) can be used directly with this method.
The effect of the conjugate amount on the incorporation,
radiochemical yield (RCY, isolated and decay corrected to the
start of reaction) and effective specific activity (SA) of the fi-
nal radioconjugates was subsequently investigated. For this
purpose three quantities of substrate (30, 40, and 60 nmol)
were radiolabelled using the same amount of [18F]fluoride ac-
tivity (ca. 1000 MBq). The incorporation of [18F]fluoride was
determined from the RP-HPLC chromatogram of the crude
reaction mixture, however unreacted [18F]fluoride can be
retained on the HPLC column which could lead to over-
estimation of the incorporation.19
As shown in Fig. 3 and Table S1,† an increase of the quan-
tities of each of the studied compounds corresponds to an
improvement of the [18F]fluoride incorporation, RCY and the
SA of the final product. Mostly, the incorporation and radio-
chemical yields appear to increase with increased amount of
conjugate. Effective specific activities of the final products
are less affected by the initial substrate quantity. However,
full optimisation of the [18F]AlF radiolabelling was beyond
the scope of this work and would be largely dependent on
the local requirements of the application for the
radioconjugate.
A single final purification step using HLB-SPE was suffi-
cient to access the final radioconjugates with a RCP >98%
(Fig. S2B, S3B, and S4B†). To ensure that the SPE cartridge
was efficiently trapping the products and therefore providing
the best RCY possible, a test using two cartridges placed in
series was carried out. The presence of a negligible amount
of radioactivity trapped on the second cartridge confirmed
that the products were efficiently loaded by the automated
system and were effectively trapped onto the HLB-SPE car-
tridge. The radioconjugates were eluted with 50% EtOH/H2O
(300–500 μL) and were suitable for use in pre-clinical applica-
tions after dilution with either PBS or 0.9% sodium chloride
solution. The total production time was 35 min. A schematic
representation of the GE TRACERlab FXFN system is shown
in Fig. 2 together with a list of the radiolabelling reaction
steps. A more detailed description of the automated
radiolabelling process can be found in the ESI† (Materials
and methods, Section 3).
Automated synthesis and formulation using the Trasis AIO
platform and comparison with the GE TRACERlab FXFN
system
The radiosynthesis of the three [18F]AlF radioconjugates was
performed on the Trasis AIO platform using the best
radiolabelling conditions acquired from the GE TRACERlab
FXFN system. In brief, 60 nmol of each conjugate was reacted
with non-purified [18F]fluoride (300–380 μl aliquot, ca. 1000
MBq, of ca. 2 mL target water), AlCl3 (1 : 0.9 substrate to Al
3+
molar ratio) at pH 4 (achieved using NaOAc buffer 25 mM).
Acetonitrile was used as organic co-solvent (aqueous solution
to organic solvent ratio of 1 : 1.2 v/v) and the reaction mixture
was incubated at 105 °C for 15 min.
A schematic representation of the Trasis AIO system is
shown in Fig. 5 together with a list of the radiolabelling reac-
tion steps. A more detailed description of the automated
radiolabelling process can be found in the ESI† (Materials
and methods, Section 4).
The production time was 26 min. [18F]AlF-NODA-Tz and
[18F]AlF-NOTA-octreotide showed a >60% [18F]fluoride incor-
poration, a >45% RCY, and a >10 MBq nmol−1 SA (Table 1).
As seen in Fig. 4, the [18F]fluoride incorporation, the RCY
and SA of the radioconjugates were generally higher when
the Trasis AIO platform was used compared to the GE
Fig. 3 Correlation between the quantity of substrate and [18F]fluoride incorporation degree (A), RCY (isolated and decay corrected to the start of
reaction) (B) and SA (effective specific activity) (C) using the GE TRACERlab FXFN system using ca. 1000 MBq of non-purified [
18F]fluoride. The reac-
tions were performed in triplicate (n = 3). The results are presented as mean ± SD.
Table 1 Radiolabelling efficiency using the cassette based Trasis AIO
platform with ca. 1000 MBq of non-purified [18F]fluoride. Reactions were
performed in triplicate (n = 3) and the results are presented as mean ±









NODA-Tz 60 68.1 ± 6.1 48.2 ± 1.4 11.4 ± 2.0
NOTA-RGDfK 60 48.3 ± 10.6 15.3 ± 6.5 7.4 ± 1.1
NOTA-octreotide 60 75.0 ± 1.8 56.2 ± 4.2 12.7 ± 0.14
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TRACERlab FXFN system. The effective control over the move-
ment of reagents and reaction mixtures around the Trasis
AIO cartridge based system may be responsible for that. How-
ever, the overall production efficiency of the [18F]AlF-NOTA-
RGDfK radioconjugate showed minimal variation between
the two platforms. This suggests that the radiolabelling pro-
cedure and purification were dependent not only on the reac-
tion conditions but also on the physical and structural prop-
erties of the molecules of interest (e.g. amino acid sequence,
chain length) which could influence the interaction with the
Fig. 4 Comparison of the [18F]fluoride incorporation degree (A), RCY (isolated and decay corrected to the start of reaction) (B) and SA (effective
specific activity) (C) between the GE TRACERlab FXFN and Trasis AIO automated synthesis platforms when 60 nmol of each precursor and a non-
purified [18F]fluoride activity of ca. 1000 MBq were used. Statistical significance was determined using a paired t-test (*P < 0.05).
Fig. 5 Schematic representation of the [18F]AlF radiochemistry set up (A) and overview of the automated radiolabelling processes (B) for the Trasis
AIO system.
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surfaces of the reaction vessels and tubing of the automation
platform.
The general radiolabelling method described here can be
used as a starting point for further optimisation to progress a
substrate of interest into a clinical setting.
Conclusions
Automated processes are typically required for the production
of good manufacturing process (GMP) compliant fluorine-18
radiopharmaceuticals. Examples of PET imaging agents
manufactured using this approach include [18F]FLT, [18F]
FAZA, [18F]HX4 and [18F]ICMT-11; where the use of auto-
mated platforms has facilitated the progression of these ra-
diotracers into the clinic.20–24 Automation of radiopharma-
ceutical production is desirable to reduce the risk to patients
by enabling batch reporting/record keeping, management
control and standardisation of processes through the use of
standard operating practices (SOPs). Furthermore, produc-
tion methods are carefully validated to ensure that processes
do not introduce pyrogens, microbes or particles into the fi-
nal patient dose. In addition to reducing the radiochemists
contact with the final product, the automation of
radiosynthesis and dispensing of the patient dose may re-
duce the number of batch failures resulting from human er-
ror. Automated synthesis modules, particularly cassette based
systems, are ideal for use in GMP radiosynthesis as most
components are easy to obtain in sterilised packaging and
are disposable after a single production run, eliminating the
need to further validate a post-production cleaning step. Sec-
ondly, these systems are easy to shield which addresses radia-
tion safety concerns associated with handling large amounts
of radioactivity.25
This study aimed to develop a general method suitable for
the automation of [18F]AlF radiochemistry which was applied
to the GE TRACERlab FXFN and Trasis AIO platforms. The
radiolabelling conditions were studied using a selection of
azamacrocycle-containing molecules including two commer-
cially available peptides and one in-house synthesised small
molecule. Initially, the [18F]AlF radiochemistry was developed
using the GE TRACERlab FXFN system and subsequently
transferred to the Trasis AIO platform. Purification of the
products by HLB-SPE was sufficient to provide
radioconjugates with high radiochemical purity (>98%) and
the total reaction times were 26–35 min. Currently, the
method described is suitable for accessing radioconjugates
for pre-clinical studies. Further work would be required to
maximise radiochemical yield for a chosen substrate and to
optimise the purity profile of the final product prior to pa-
tient use. This process should ensure that regulatory parame-
ters are met. The production of large radioactivity batches of
GMP grade radiopharmaceuticals for multi-patient doses al-
lows off-site transportation to “satellite” PET centres and fa-
cilitates commercial accessibility to these imaging agents. Al-
though the final products were successfully prepared using
both automated systems, the cassette based Trasis AIO en-
abled the highest [18F]fluoride incorporation and gave prod-
ucts with the highest RCY and SA compared to the GE
TRACERlab FXFN, most likely due to a greater control over re-
agent handling. Both the GE TRACERlab FXFN and Trasis AIO
systems can be used for the [18F]AlF radiolabelling of pep-
tides and small molecules and have great potential for the
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